New 52 Week Low Today

ACADIA Pharmaceuticals Inc ACAD:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:14 PM EDT
14.89quote price arrow up+0.03 (+0.20%)
Volume
71,759
Close
14.86quote price arrow down-0.32 (-2.11%)
Volume
2,854,516
52 week range
14.72 - 33.99
Loading...
  • Open15.35
  • Day High15.40
  • Day Low14.72
  • Prev Close15.18
  • 52 Week High33.99
  • 52 Week High Date07/18/23
  • 52 Week Low14.72
  • 52 Week Low Date05/14/24

Key Stats

  • Market Cap2.455B
  • Shares Out165.22M
  • 10 Day Average Volume2.02M
  • Dividend-
  • Dividend Yield-
  • Beta0.41
  • YTD % Change-52.54

KEY STATS

  • Open15.35
  • Day High15.40
  • Day Low14.72
  • Prev Close15.18
  • 52 Week High33.99
  • 52 Week High Date07/18/23
  • 52 Week Low14.72
  • 52 Week Low Date05/14/24
  • Market Cap2.455B
  • Shares Out165.22M
  • 10 Day Average Volume2.02M
  • Dividend-
  • Dividend Yield-
  • Beta0.41
  • YTD % Change-52.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.01
  • P/E (TTM)-1,151.94
  • Fwd P/E (NTM)26.02
  • EBITDA (TTM)6.069M
  • ROE (TTM)-0.41%
  • Revenue (TTM)813.806M
  • Gross Margin (TTM)92.27%
  • Net Margin (TTM)-0.21%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/31/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On ACADIA Pharmaceuticals Inc

 

Profile

MORE
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE...
Stephen Biggar M.D., Ph.D.
Independent Chairman of the Board
Stephen Davis CPA
Chief Executive Officer, Director
Brendan Teehan
Chief Operating Officer, Executive Vice President, Head of Commercial
Mark Schneyer
Chief Financial Officer, Executive Vice President
Douglas Williamson
Executive Vice President - Research and Development
Address
12830 El Camino Real, Suite 400
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
MYGN
Myriad Genetics Inc
25.36+0.43+1.72%
PTCT
PTC Therapeutics Inc
31.18-0.52-1.64%
GLPG
Galapagos NV
28.63+0.16+0.56%
GH
Guardant Health Inc
24.73+0.73+3.04%
TXG
10X Genomics Inc
26.56-0.41-1.52%